# Osimertinib In EGFR Mutant Lung Cancer

> **NCT03586453** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 30 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT03586453
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-08-13
- **Primary completion:** 2028-02-28
- **Final completion:** 2028-09-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-04-29

## Collaborators

- AstraZeneca

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03586453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03586453, "Osimertinib In EGFR Mutant Lung Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03586453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*